Literature DB >> 26370509

The New State of the Art: Cas9 for Gene Activation and Repression.

Marie F La Russa1, Lei S Qi2.   

Abstract

CRISPR-Cas9 technology has rapidly changed the landscape for how biologists and bioengineers study and manipulate the genome. Derived from the bacterial adaptive immune system, CRISPR-Cas9 has been coopted and repurposed for a variety of new functions, including the activation or repression of gene expression (termed CRISPRa or CRISPRi, respectively). This represents an exciting alternative to previously used repression or activation technologies such as RNA interference (RNAi) or the use of gene overexpression vectors. We have only just begun exploring the possibilities that CRISPR technology offers for gene regulation and the control of cell identity and behavior. In this review, we describe the recent advances of CRISPR-Cas9 technology for gene regulation and outline advantages and disadvantages of CRISPRa and CRISPRi (CRISPRa/i) relative to alternative technologies.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Mesh:

Year:  2015        PMID: 26370509      PMCID: PMC4609748          DOI: 10.1128/MCB.00512-15

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  82 in total

1.  Automatic identification of subcellular phenotypes on human cell arrays.

Authors:  Christian Conrad; Holger Erfle; Patrick Warnat; Nathalie Daigle; Thomas Lörch; Jan Ellenberg; Rainer Pepperkok; Roland Eils
Journal:  Genome Res       Date:  2004-06       Impact factor: 9.043

Review 2.  Revealing the world of RNA interference.

Authors:  Craig C Mello; Darryl Conte
Journal:  Nature       Date:  2004-09-16       Impact factor: 49.962

Review 3.  Designing transcription factor architectures for drug discovery.

Authors:  Pilar Blancafort; David J Segal; Carlos F Barbas
Journal:  Mol Pharmacol       Date:  2004-08-31       Impact factor: 4.436

4.  Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing.

Authors:  Gunter Meister; Markus Landthaler; Yair Dorsett; Thomas Tuschl
Journal:  RNA       Date:  2004-03       Impact factor: 4.942

5.  C. elegans ORFeome version 1.1: experimental verification of the genome annotation and resource for proteome-scale protein expression.

Authors:  Jérôme Reboul; Philippe Vaglio; Jean-François Rual; Philippe Lamesch; Monica Martinez; Christopher M Armstrong; Siming Li; Laurent Jacotot; Nicolas Bertin; Rekin's Janky; Troy Moore; James R Hudson; James L Hartley; Michael A Brasch; Jean Vandenhaute; Simon Boulton; Gregory A Endress; Sarah Jenna; Eric Chevet; Vasilis Papasotiropoulos; Peter P Tolias; Jason Ptacek; Mike Snyder; Raymond Huang; Mark R Chance; Hongmei Lee; Lynn Doucette-Stamm; David E Hill; Marc Vidal
Journal:  Nat Genet       Date:  2003-05       Impact factor: 38.330

6.  Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation.

Authors:  John G Doench; Ella Hartenian; Daniel B Graham; Zuzana Tothova; Mudra Hegde; Ian Smith; Meagan Sullender; Benjamin L Ebert; Ramnik J Xavier; David E Root
Journal:  Nat Biotechnol       Date:  2014-09-03       Impact factor: 54.908

7.  Human ORFeome version 1.1: a platform for reverse proteomics.

Authors:  Jean-François Rual; Tomoko Hirozane-Kishikawa; Tong Hao; Nicolas Bertin; Siming Li; Amélie Dricot; Ning Li; Jennifer Rosenberg; Philippe Lamesch; Pierre-Olivier Vidalain; Tracey R Clingingsmith; James L Hartley; Dominic Esposito; David Cheo; Troy Moore; Blake Simmons; Reynaldo Sequerra; Stephanie Bosak; Lynn Doucette-Stamm; Christian Le Peuch; Jean Vandenhaute; Michael E Cusick; Joanna S Albala; David E Hill; Marc Vidal
Journal:  Genome Res       Date:  2004-10       Impact factor: 9.043

8.  Toward controlling gene expression at will: specific regulation of the erbB-2/HER-2 promoter by using polydactyl zinc finger proteins constructed from modular building blocks.

Authors:  R R Beerli; D J Segal; B Dreier; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

9.  Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds.

Authors:  Jesse G Zalatan; Michael E Lee; Ricardo Almeida; Luke A Gilbert; Evan H Whitehead; Marie La Russa; Jordan C Tsai; Jonathan S Weissman; John E Dueber; Lei S Qi; Wendell A Lim
Journal:  Cell       Date:  2014-12-18       Impact factor: 41.582

10.  Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation.

Authors:  Luke A Gilbert; Max A Horlbeck; Britt Adamson; Jacqueline E Villalta; Yuwen Chen; Evan H Whitehead; Carla Guimaraes; Barbara Panning; Hidde L Ploegh; Michael C Bassik; Lei S Qi; Martin Kampmann; Jonathan S Weissman
Journal:  Cell       Date:  2014-10-09       Impact factor: 41.582

View more
  63 in total

Review 1.  A CRISPR Path to Engineering New Genetic Mouse Models for Cardiovascular Research.

Authors:  Joseph M Miano; Qiuyu Martin Zhu; Charles J Lowenstein
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-04-21       Impact factor: 8.311

Review 2.  Applied Bioengineering in Tissue Reconstruction, Replacement, and Regeneration.

Authors:  Juan M Colazo; Brian C Evans; Angel F Farinas; Salam Al-Kassis; Craig L Duvall; Wesley P Thayer
Journal:  Tissue Eng Part B Rev       Date:  2019-08       Impact factor: 6.389

Review 3.  Molecular phenotyping of infection-associated small non-coding RNAs.

Authors:  Lars Barquist; Alexander J Westermann; Jörg Vogel
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-11-05       Impact factor: 6.237

4.  In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation.

Authors:  Hsin-Kai Liao; Fumiyuki Hatanaka; Toshikazu Araoka; Pradeep Reddy; Min-Zu Wu; Yinghui Sui; Takayoshi Yamauchi; Masahiro Sakurai; David D O'Keefe; Estrella Núñez-Delicado; Pedro Guillen; Josep M Campistol; Cheng-Jang Wu; Li-Fan Lu; Concepcion Rodriguez Esteban; Juan Carlos Izpisua Belmonte
Journal:  Cell       Date:  2017-12-07       Impact factor: 41.582

Review 5.  Prospects for engineering dynamic CRISPR-Cas transcriptional circuits to improve bioproduction.

Authors:  Jason Fontana; William E Voje; Jesse G Zalatan; James M Carothers
Journal:  J Ind Microbiol Biotechnol       Date:  2018-05-08       Impact factor: 3.346

6.  A Multipurpose Toolkit to Enable Advanced Genome Engineering in Plants.

Authors:  Tomáš Čermák; Shaun J Curtin; Javier Gil-Humanes; Radim Čegan; Thomas J Y Kono; Eva Konečná; Joseph J Belanto; Colby G Starker; Jade W Mathre; Rebecca L Greenstein; Daniel F Voytas
Journal:  Plant Cell       Date:  2017-05-18       Impact factor: 11.277

7.  Mapping Cellular Reprogramming via Pooled Overexpression Screens with Paired Fitness and Single-Cell RNA-Sequencing Readout.

Authors:  Udit Parekh; Yan Wu; Dongxin Zhao; Atharv Worlikar; Neha Shah; Kun Zhang; Prashant Mali
Journal:  Cell Syst       Date:  2018-11-14       Impact factor: 10.304

8.  Developmental Sensitivity in Schistosoma mansoni to Puromycin To Establish Drug Selection of Transgenic Schistosomes.

Authors:  Hong-Bin Yan; Michael J Smout; Chuan Ju; Anne E Folley; Danielle E Skinner; Victoria H Mann; Alex Loukas; Wei Hu; Paul J Brindley; Gabriel Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

9.  CRISPR/Cas9 in allergic and immunologic diseases.

Authors:  Michael A Goodman; Donya Moradi Manesh; Punam Malik; Marc E Rothenberg
Journal:  Expert Rev Clin Immunol       Date:  2016-10-24       Impact factor: 4.473

10.  Modulating Gene Expression in Epstein-Barr Virus (EBV)-Positive B Cell Lines with CRISPRa and CRISPRi.

Authors:  Liang Wei Wang; Stephen J Trudeau; Chong Wang; Catherine Gerdt; Sizun Jiang; Bo Zhao; Benjamin E Gewurz
Journal:  Curr Protoc Mol Biol       Date:  2018-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.